Statistics
Publications
4
Citations
84
H-Index
4
Active since
2019
Affiliations
Rebecca L. Kelly is an author at Mayo Clinic specializing in oncology, parp inhibition, and cancer pharmacology.
Publications per year
2019–2024
4
4
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo
Nicole D. Vincelette, Husheng Ding, Amelia M. Huehls et al. · Scientific Reports · 2019 · 13 citations · Full text
Medicine, Oncology, Pharmacology +17
Brazilin is a natural product inhibitor of the NLRP3 inflammasome
Emily McMahon, Sherihan El‐Sayed, Jack Green et al. · iScience · 2024 · 13 citations · Full text
1–4 of 4